FORA Capital LLC Acquires Shares of 106,078 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

FORA Capital LLC bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 106,078 shares of the company's stock, valued at approximately $2,338,000.

Other hedge funds have also recently bought and sold shares of the company. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $66,000. Finally, IFP Advisors Inc lifted its position in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after buying an additional 1,960 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TEVA. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and an average price target of $23.71.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $1.13 during trading on Friday, hitting $16.94. The stock had a trading volume of 19,072,081 shares, compared to its average volume of 10,028,635. The company has a 50 day moving average price of $15.18 and a 200-day moving average price of $17.44. The firm has a market cap of $19.21 billion, a price-to-earnings ratio of -11.68, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company's revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.48 EPS. As a group, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.